Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates

Executive Summary

OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil

You may also be interested in...



Roche EGRF Outlook: Iressa Review Gives “Encouragement” To Tarceva 

Roche's outlook for Tarceva in non-small cell lung cancer received a "margin of encouragement" from the Iressa FDA advisory committee review, Pharmaceuticals Head William Burns said on a conference call Oct. 10

Millennium/EntreMed Show Opposite Ends Of Biotech Hype Cycle

Wall Street's muted reaction to Millennium's recent announcements of progress in understanding the genetic basis of obesity illustrates the fickle nature of hype involving biotechnology research.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel